JP2015529236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529236A5 JP2015529236A5 JP2015532465A JP2015532465A JP2015529236A5 JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5 JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- fragment
- region
- protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 51
- 102000018358 immunoglobulin Human genes 0.000 claims 51
- 239000012634 fragment Substances 0.000 claims 42
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000004048 modification Effects 0.000 claims 18
- 238000012986 modification Methods 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 16
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 13
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000833 heterodimer Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229940072221 immunoglobulins Drugs 0.000 claims 10
- 101710120037 Toxin CcdB Proteins 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 101100504121 Mus musculus Ighg gene Proteins 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 101001055315 Homo sapiens Immunoglobulin heavy constant alpha 1 Proteins 0.000 claims 2
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 claims 2
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 claims 2
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims 2
- 102100026217 Immunoglobulin heavy constant alpha 1 Human genes 0.000 claims 2
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims 2
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 claims 2
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705278P | 2012-09-25 | 2012-09-25 | |
| US61/705,278 | 2012-09-25 | ||
| PCT/EP2013/069989 WO2014049003A1 (en) | 2012-09-25 | 2013-09-25 | Purification of hetero-dimeric immunoglobulins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Division JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Division JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529236A JP2015529236A (ja) | 2015-10-05 |
| JP2015529236A5 true JP2015529236A5 (enExample) | 2016-11-10 |
Family
ID=49237223
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532465A Pending JP2015529236A (ja) | 2012-09-25 | 2013-09-25 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150239991A1 (enExample) |
| EP (2) | EP2900696A1 (enExample) |
| JP (5) | JP2015529236A (enExample) |
| KR (1) | KR20150076172A (enExample) |
| CN (1) | CN104968685A (enExample) |
| AU (2) | AU2013322710A1 (enExample) |
| CA (2) | CA2886036A1 (enExample) |
| HK (1) | HK1215950A1 (enExample) |
| IL (2) | IL237872B (enExample) |
| IN (1) | IN2015MN00139A (enExample) |
| WO (1) | WO2014049003A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
| RU2013141078A (ru) | 2011-02-28 | 2015-04-10 | Ф. Хоффманн-Ля Рош Аг | Одновалентные антигенсвязывающие белки |
| IN2015MN00139A (enExample) * | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| CA2922979A1 (en) * | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
| CN105873953A (zh) * | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| JP6778110B2 (ja) | 2014-01-15 | 2020-10-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改善されたプロテインＡ結合を有するＦｃ領域バリアント |
| TN2017000532A1 (en) | 2014-03-28 | 2019-04-12 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3. |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| CN106573986A (zh) * | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| WO2017005649A1 (en) | 2015-07-09 | 2017-01-12 | Genmab A/S | Bispecific and multispecific antibodies and method for isolation of such |
| CN116675776A (zh) * | 2015-10-25 | 2023-09-01 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| CN109476732B (zh) | 2016-04-13 | 2024-03-22 | 赛诺菲 | 三特异性和/或三价结合蛋白 |
| MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| BR112018069890A2 (pt) * | 2016-05-02 | 2019-02-05 | Hoffmann La Roche | polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão |
| BR112019006074A2 (pt) | 2016-09-29 | 2019-06-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo |
| TN2019000161A1 (en) | 2016-11-18 | 2020-10-05 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof |
| CN110770255B (zh) | 2017-04-11 | 2025-07-01 | 因荷布瑞克斯生物科学公司 | 具有受限cd3结合的多特异性多肽构建体及其使用方法 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| MX2020010638A (es) | 2018-04-11 | 2021-01-08 | Inhibrx Inc | Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados. |
| FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
| JP2021528435A (ja) * | 2018-06-22 | 2021-10-21 | ゲンマブ エー／エス | ２つ以上の異なる抗体の制御された混合物を産生するための方法 |
| JP7651450B2 (ja) | 2018-07-24 | 2025-03-26 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法 |
| JP2022504802A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | ５ｔ４シングルドメイン抗体およびその治療組成物 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| CA3115285A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| JP2022512684A (ja) | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物 |
| MX2021007677A (es) | 2018-12-24 | 2021-12-10 | Sanofi Sa | Proteinas de union multiespecificas basadas en pseudofab. |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2022006972A (es) * | 2019-12-26 | 2022-08-04 | Abl Bio Inc | Metodo para la purificacion de peptido biologicamente activo utilizando cromatografia de afinidad con proteina a. |
| MX2022009306A (es) | 2020-01-29 | 2022-09-26 | Inhibrx Inc | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. |
| MX2023004054A (es) | 2020-10-07 | 2023-06-29 | Dren Bio Inc | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. |
| US20240279341A1 (en) | 2021-06-16 | 2024-08-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| JP2023092810A (ja) * | 2021-12-22 | 2023-07-04 | 国立大学法人東京農工大学 | 変異抗体、変異抗体の製造方法 |
| JP2025519477A (ja) | 2022-06-07 | 2025-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性を調節するための多重特異性分子及びその使用 |
| JP2025528751A (ja) | 2022-07-29 | 2025-09-02 | アレクトル エルエルシー | Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法 |
| AU2023314807A1 (en) | 2022-07-29 | 2025-03-06 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| AU2023334360A1 (en) * | 2022-09-02 | 2025-03-06 | Zoetis Services Llc | Equine antibody mutants |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025087386A1 (zh) * | 2023-10-25 | 2025-05-01 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
| MX2007015051A (es) * | 2005-06-17 | 2008-01-18 | Wyeth Corp | Metodos para purificar proteinas que contienen la region fc. |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| CA2678181C (en) | 2007-02-16 | 2016-12-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| ME02485B (me) * | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
| MX2011006870A (es) * | 2008-12-23 | 2011-07-19 | Genentech Inc | Variantes de inmunoglobulina con union alterada a proteina a. |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| KR102103093B1 (ko) * | 2009-12-25 | 2020-04-21 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| JP6040148B2 (ja) * | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| BR112013023918A2 (pt) | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
| US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
| PL2771364T3 (pl) * | 2011-10-27 | 2020-01-31 | Genmab A/S | Wytwarzanie heterodimerycznych białek |
| CN104137107A (zh) | 2012-03-06 | 2014-11-05 | 福斯分析有限公司 | 用于为化学计量分析形成预测模型的方法、软件和图形用户界面 |
| EP3517548A1 (en) | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| IN2015MN00139A (enExample) * | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
| CN105873953A (zh) * | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
-
2013
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Ceased
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/en not_active Ceased
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/en not_active Ceased
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/en not_active Withdrawn
- 2013-09-25 CA CA2886036A patent/CA2886036A1/en not_active Abandoned
- 2013-09-25 CA CA3061557A patent/CA3061557A1/en active Pending
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 HK HK16103843.5A patent/HK1215950A1/zh unknown
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja not_active Ceased
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529236A5 (enExample) | ||
| JP6856610B2 (ja) | ヘテロ二量体免疫グロブリンの精製 | |
| KR102440737B1 (ko) | 이중특이적 항체에 대한 정제 플랫폼 | |
| JP6273219B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP5816170B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP2020506898A5 (enExample) | ||
| JP2020515518A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| FI2560993T3 (fi) | Heterodimeeristä vasta-ainetta FC sisältävät proteiinit ja menetelmät niiden tuottamiseksi | |
| JP2011505810A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| EP3026060A1 (en) | Humanized antibody or fragment thereof specific for CD45R0 | |
| JP2013520984A5 (enExample) | ||
| JP2016518333A5 (enExample) | ||
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| JP7653920B2 (ja) | 多段階クロマトグラフィープロセス中の望ましくない成分を除去する方法 | |
| AU2023207604A1 (en) | Methods for improving resolution of heterodimeric proteins from impurities using affinity chromatography | |
| CN121319108A (zh) | 在多级色谱过程期间去除非期望的组分的方法 | |
| EA049572B1 (ru) | Способы удаления нежелательных компонентов в многостадийных хроматографических процессах | |
| NZ737843B2 (en) | Tau-binding antibodies | |
| TH143301A (th) | นิวทรอลไลซ์ซิ่ง แอนติ-CCL-20 แอนติบอดี้ (NEUtralizing Anti-CCL-20 Antibodies) | |
| NZ774327B2 (en) | Therapeutic antibodies and their uses | |
| NZ724772B2 (en) | ANTIBODIES AGAINST HPA-1a |